Live News EQUITY FLASH L impact Oct 26, 2026, 12:35 PM UTC Nuvectis Reports 40% Response Rate in Phase 1b Glioma Study Nuvectis reported a 40% response rate for NXP200 in a Phase 1b high-grade glioma study. NVCT SquawkNews Desk